These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 28351053)

  • 1. Macular Edema - Rationale for Therapy.
    Wolfensberger TJ
    Dev Ophthalmol; 2017; 58():74-86. PubMed ID: 28351053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Macular edema--rationale for therapy.
    Wolfensberger TJ; Gregor ZJ
    Dev Ophthalmol; 2010; 47():49-58. PubMed ID: 20703043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Macular edema. Miscellaneous.
    Creuzot-Garcher C; Wolf S
    Dev Ophthalmol; 2010; 47():183-198. PubMed ID: 20703051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resolution of diabetic macular edema after surgical removal of the posterior hyaloid and the inner limiting membrane.
    Gandorfer A; Messmer EM; Ulbig MW; Kampik A
    Retina; 2000; 20(2):126-33. PubMed ID: 10783944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema.
    Haritoglou C; Kook D; Neubauer A; Wolf A; Priglinger S; Strauss R; Gandorfer A; Ulbig M; Kampik A
    Retina; 2006; 26(9):999-1005. PubMed ID: 17151486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema.
    Kook D; Wolf A; Kreutzer T; Neubauer A; Strauss R; Ulbig M; Kampik A; Haritoglou C
    Retina; 2008 Oct; 28(8):1053-60. PubMed ID: 18779710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surgical macular decompression for macular edema in retinal vein occlusion.
    Mandelcorn MS; Mandelcorn E; Guan K; Adatia FA
    Can J Ophthalmol; 2007 Feb; 42(1):116-22. PubMed ID: 17361252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vitreomacular traction in a case of exudative age-related macular degeneration resistant to anti-VEGF therapy.
    Shah SU; Haller JA
    Acta Ophthalmol; 2012 Nov; 90(7):e569-70. PubMed ID: 22429537
    [No Abstract]   [Full Text] [Related]  

  • 9. [Angiopathy and the eye].
    Rencová E
    Vnitr Lek; 2010 Apr; 56(4):333-9. PubMed ID: 20465107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Indirect laser treatment and anti-VEGF therapy of a retinal angioma, with resolution of a large serous retinal detachment, macular exudates, and macular edema.
    Rarey K; Friberg TR
    Semin Ophthalmol; 2010; 25(1-2):21-6. PubMed ID: 20507193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RANIBIZUMAB PLUS PROMPT OR DEFERRED LASER FOR DIABETIC MACULAR EDEMA IN EYES WITH VITRECTOMY BEFORE ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY.
    Bressler SB; Melia M; Glassman AR; Almukhtar T; Jampol LM; Shami M; Berger BB; Bressler NM;
    Retina; 2015 Dec; 35(12):2516-28. PubMed ID: 26035510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional and morphological changes in diabetic macular edema over the course of anti-vascular endothelial growth factor treatment.
    Reznicek L; Cserhati S; Seidensticker F; Liegl R; Kampik A; Ulbig M; Neubauer AS; Kernt M
    Acta Ophthalmol; 2013 Nov; 91(7):e529-36. PubMed ID: 23647578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current treatment approaches in diabetic macular edema.
    Meyer CH
    Ophthalmologica; 2007; 221(2):118-31. PubMed ID: 17380066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distribution of intraretinal exudates in diabetic macular edema during anti-vascular endothelial growth factor therapy observed by spectral domain optical coherence tomography and fundus photography.
    Pemp B; Deák G; Prager S; Mitsch C; Lammer J; Schmidinger G; Scholda C; Schmidt-Erfurth U; Bolz M;
    Retina; 2014 Dec; 34(12):2407-15. PubMed ID: 25062440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vitrectomy with peeling of the inner limiting membrane for treating diabetic macular edema.
    Kolacny D; Parys-Vanginderdeuren R; Van Lommel A; Stalmans P
    Bull Soc Belge Ophtalmol; 2005; (296):15-23. PubMed ID: 16050416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predicting outcomes to anti-vascular endothelial growth factor (VEGF) therapy in diabetic macular oedema: a review of the literature.
    Ashraf M; Souka A; Adelman R
    Br J Ophthalmol; 2016 Dec; 100(12):1596-1604. PubMed ID: 27231313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Corticosteroids inhibit VEGF-induced vascular leakage in a rabbit model of blood-retinal and blood-aqueous barrier breakdown.
    Edelman JL; Lutz D; Castro MR
    Exp Eye Res; 2005 Feb; 80(2):249-58. PubMed ID: 15670803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Combined pharmacosurgery as treatment for diabetic macular edema: core pars plana vitrectomy and intravitreal injection of bevacizumab and triamcinolone].
    Naser H; Koss MJ; Singh P; Koch F
    Klin Monbl Augenheilkd; 2011 Oct; 228(10):910-4. PubMed ID: 21997827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Vitrectomy with peeling retinal limiting membrane (ILM) in eyes with diabetic macular edema].
    Oficjalska-Młyńczak J; Jamrozy-Witkowska A; Muzyka-Woźniak M; Turno-Krecicka A; Gołebiowska B
    Klin Oczna; 2006; 108(7-9):273-7. PubMed ID: 17290822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Macular hypotrophy after internal limiting membrane removal for diabetic macular edema.
    Romano MR; Romano V; Vallejo-Garcia JL; Vinciguerra R; Romano M; Cereda M; Angi M; Valldeperas X; Costagliola C; Vinciguerra P
    Retina; 2014 Jun; 34(6):1182-9. PubMed ID: 24846134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.